This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
3 May 2011

Grifols & Talecris Sign Consent Agreement for Merger

Grifols has agreed to the sale of select assets and has entered into certain commercial, lease and manufacturing agreements with the Italian company Kedrion for as many as seven years.

Spanish drugmaker Grifols, S.A. and Talecris Biotherapeutics announced Monday that they have signed a consent agreement with the U.S. Federal Trade Commission (FTC) outlining the conditions for Grifols’ acquisition of Talecris. 

 

Grifols has agreed to the sale of select assets and has entered into certain commercial, lease and manufacturing agreements with the Italian company Kedrion for as many as seven years.

 

Kedrion and Grifols will have a contract manufacturing agreement to fractionate and purify Kedrion’s plasma and to deliver IVIG and Albumin under Kedrion’s private label, and Factor VIII under the trade name Koate, for sale in the U.S.

Related News